PTEN is destabilized by phosphorylation on Thr^{366}

Helene MACCARIO¹, Nevin M. PERERA¹, Lindsay DAVIDSON, C. Peter DOWNES and Nick R. LESLIE²
Division of Molecular Physiology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Although PTEN (phosphatase and tensin homologue deleted on chromosome 10) is one of the most commonly mutated tumour suppressors in human cancers, loss of PTEN expression in the absence of mutation appears to occur in an even greater number of tumours. PTEN is phosphorylated in vitro on Thr^{366} and Ser^{370} by GSK3 (glycogen synthase kinase 3) and CK2 (casein kinase 2) respectively, and specific inhibitors of these kinases block these phosphorylation events in cultured cells. Although mutation of these phosphorylation sites did not alter the phosphatase activity of PTEN in vitro or in cells, blocking phosphorylation of Thr^{366} by either mutation or GSK3 inhibition in glioblastoma cell lines led to a stabilization of the PTEN protein. Our data support a model in which the phosphorylation of Thr^{366} plays a role in destabilizing the PTEN protein.

Key words: phosphatase, phosphoinositide, protein stability, PTEN (phosphatase and tensin homologue deleted on chromosome 10), tumour suppressor.

INTRODUCTION

PTEN (phosphatase and tensin homologue deleted on chromosome 10) regulates many cellular processes, including cell proliferation, survival, growth and motility, principally by inhibiting PI3K (phosphoinositide 3-kinase)-dependent signalling via its PtdIns(3,4,5)P³, phosphatase activity [1,2]. It is one of the most commonly mutated tumour suppressors in human cancers, with genetic alterations occurring in a wide range of human tumour types, but at especially high frequency in endometrial carcinoma and glioblastoma [3]. However, evidence has indicated that loss of PTEN expression in the absence of biallelic mutation occurs even more frequently [4–7]. Although possible mechanisms causing the lack of expression of PTEN in tumours retaining at least one wild-type PTEN copy have been identified, such as promoter methylation [8–10], it appears that other, unknown, mechanisms may be acting in many tumours [9,10]. Understanding the mechanisms regulating PTEN expression seems to be particularly important, as, unlike many tumour suppressors, strong evidence indicates that partial loss of PTEN expression can enhance tumour development [11–13].

It is clear that PTEN stability can be regulated through the C-terminal tail, which is phosphorylated upon a cluster of serine and threonine residues, Ser⁴⁰⁰, Thr^{362}, Thr^{366} and Ser^{385}. This phosphorylation appears to stabilize the PTEN protein as well as to inhibit its biological activity [14,15]. Also, a protein named PICT1/GLTSCR2 (protein interacting with C-terminal tail 1/glioma tumour suppressor candidate region gene 2) has been described that binds to the C-terminal tail of PTEN, knockdown of which by RNAi (RNA interference) also leads to reduced PTEN protein stability [16]. Although PTEN ubiquitination and proteasomal degradation have been implicated previously [15,17,18], it has recently been shown that PTEN stability can be regulated through ubiquitination mediated by the NEDD4-1 ubiquitin ligase [19]. Although it seems likely that C-terminal cluster phosphorylation regulates PTEN stability through regulating a conformational change in the protein [20], and thus ubiquitination, further mechanistic details are not yet clear [21–24].

Two other phosphorylation sites within the PTEN C-terminal tail have been identified, Ser^{370} and Thr^{366} [23,25]. Ser^{370} was first identified as a phosphorylation site by metabolic labelling and mutational analysis and also by MS [23,25]. It can be phosphorylated efficiently in vitro by CK2 (casein kinase 2). Thr^{366} was identified as a phosphorylation site based upon the combined use of MS, mutational analysis and the use of phosphothreonine/proline-specific antibodies [25]. It appears to be phosphorylated efficiently in vitro and probably in cells by GSK3 (glycogen synthase 3) [25]. In the present study, we have raised phospho-specific antibodies to phospho-Ser^{370} and phospho-Thr^{366}, and used these to analyse the phosphorylation of these sites by CK2 and GSK3 respectively. We show that, although the phosphorylation of these sites does not appear to alter PTEN activity in vitro or in cells, phosphorylation of Thr^{366} specifically can lead to destabilization of the PTEN protein.

EXPERIMENTAL

Cell culture

U87MG glioblastoma cells and NIH 3T3 fibroblasts were obtained from the ECACC (European Collection of Animal Cell Cultures) and maintained in the recommended media. Standard cell culture media, additives and sera were from Invitrogen/Gibco. Other chemicals were from Sigma. PTEN was expressed in U87MG cells using an adapted baculoviral delivery system. Adapted baculoviruses containing the PTEN cDNA downstream of a CMV (cytomegalovirus) promoter were prepared in SF9 cells, using standard protocols developed for recombinant protein expression in insect cells, and added to low-confluence U87MG cell cultures for 24 h at 5% (v/v) culture volume. The use of fluorescently marked proteins and functional studies show that this routinely led to relatively even expression of target proteins in well over 95% of the cultured U87MG cells as described previously [26]. In most experiments in U87MG cells, baculoviruses were used to express PTEN at similar levels to endogenous...
levels in other cultured cells (see for example, Supplementary Figure 1 at http://www.BiochemJ.org/bj/405/bj4050439add.htm), although, in protein stability experiments, levels were 5–10 times higher in order to help the detection of $^{35}$S-labelled PTEN in immunoprecipitates.

### Antibodies and Western blotting

Phospho-specific antibodies against PTEN phospho-Thr$^{366}$ and PTEN phospho-Ser$^{370}$ were raised using the phosphopeptides TSVT$^*$PDV and TPDVS$^*$DNE respectively (where $^*$ indicates the phosphorylation site). These peptides, along with a PTEN N-terminal peptide MTIAIKEVSNNKRR, were synthesized by Dr Graham Bloomberg (Molecular Recognition Centre, University of Bristol, Bristol, U.K.) and were injected into sheep at Diagnostics Scotland (Edinburgh, U.K.). Sheep were also immunized with full-length hexahistidine-tagged PTEN protein expressed and purified from bacteria. Antibodies were purified from serum by affinity for the immunized peptide or protein. All blotting experiments using affinity-purified phospho-specific antibodies included co-incubation with the corresponding dephosphopeptide (at 10 $\mu$g/ml) to block non-phospho-specific immunoreactivity. Mouse monoclonal (clone A2B1) and rabbit polyclonal antibodies to PTEN were purchased from Santa Cruz Biotechnology and Biosource respectively. Polyclonal antibodies to phospho-PTEN (Ser$^{380}$/Thr$^{385}$/Thr$^{393}$) and phospho-Ser$^{366}$ Akt/PKB (protein kinase B) were purchased from Cell Signaling Technologies. A rabbit polyclonal antibody raised against PTEN phospho-Ser$^{365}$ was purchased from Biosource. To prepare cellular samples for protein gel electrophoresis, the following cell lysis buffer was used: 25 mM Hepes (pH 7.4), 150 mM NaCl, 1 % Triton X-100, 0.1 % 2 mercaptoethanol, 1 mM EDTA, 1 mM EGTA, 10 mM $\beta$-glycerolphosphate, 50 mM sodium fluoride, 10 $\mu$g/ml leupeptin, 100 $\mu$M PMSF and 1 mM benzamidine. Proteins were separated by PAGE using pre-cast 4–12 % gradient gels and blotted on to PVDF membranes (Polyscreen; NEN/PerkinElmer). Most reagents for electrophoresis and blotting were purchased from Invitrogen, and standard manufacturers’ protocols were followed. Immunoprecipitation of PTEN used the A2B1 monoclonal antibody from Santa Cruz Biotechnology, pre-conjugated with agarose beads. The assay of immunoprecipitated Akt/PKB activity followed methods published previously [26,27]. Quantification was performed using AIDA image analysis software. In the case of data in Supplementary Figures 2 and 3 (at http://www.BiochemJ.org/bj/405/bj4050439add.htm), the scanned and presented images de-
Destabilization of PTEN by phosphorylation on Thr\textsuperscript{366}

Figure 1 PTEN is phosphorylated \textit{in vitro} by CK2 and GSK3

(A) Buffed recombinant PTEN, wild-type (wt), T366A mutant or S370A mutant, was phosphorylated \textit{in vitro} using CK2, GSK3\(_{\beta}\) or both kinases. PTEN protein was then analysed by Western blotting using the general (Total PTEN) and phospho-specific (P-PTEN) PTEN antibodies indicated. (B) Stoichiometry of phosphorylation by CK2 and GSK3. The stoichiometry of phosphate incorporation was calculated after phosphorylation in \textit{vitro} of wild-type PTEN, PTEN T366A or PTEN S370A with CK2 or GSK3.

Investigating the phosphorylation of PTEN Thr\textsuperscript{366} by a panel of 37 protein kinases \textit{in vitro} indicated that other protein kinases exist that can efficiently phosphorylate this site experimentally in addition to CK2 and GSK3 (results not shown). We therefore chose to address the effects on PTEN phosphorylation of a number of well-characterized small-molecule protein and lipid kinase inhibitors to determine the extent to which CK2 and GSK3 account for the phosphorylation of these sites in cells. PTEN phosphorylation upon both Thr\textsuperscript{366} and Ser\textsuperscript{370} in cells was inhibited by the CK2 inhibitor DMAT, whereas the GSK3 inhibitors CT99021 and AR-A0144-18 both inhibited the basal phosphorylation of PTEN on Thr\textsuperscript{366}, but not Ser\textsuperscript{370} (Figure 2). The specificity of these inhibitors has been tested using large panels of protein kinases \cite{31,32}. Strong suppression of phosphorylation by these inhibitors required long incubation times, of several hours or longer, and varied between cell types, being slower when PTEN was expressed in U87MG cells than with endogenous PTEN in NIH 3T3 cells (Figure 2, and results not shown). This suggests that under normal conditions dephosphorylation of these sites is slow. We also addressed other plausible or proposed mechanisms regulating PTEN phosphorylation, such as proline-directed kinase phosphorylation of Thr\textsuperscript{366}, and phosphorylation by ROCK (Rho-associated kinase)- and PI3K-dependent feedback phosphorylation \cite{22,33}. In these experiments, the phosphorylation on Thr\textsuperscript{366} and Ser\textsuperscript{370} of wild-type PTEN expressed in U87MG cells was not affected by incubation with the DYRK (dual-specificity tyrosine-phosphorylated and -regulated kinase) inhibitor harmine (10 \(\mu\)M), the MEK (mitogen-activated protein kinase/extracellular-signal-regulated kinase) inhibitor U0126 (5 \(\mu\)M), or the CDK2 (cyclin-dependent kinase 2) inhibitor roscovitine (10 \(\mu\)M) (results not shown). The phosphorylation of PTEN on Thr\textsuperscript{366} and Ser\textsuperscript{370} was not greatly affected by the PI3K inhibitors LY294002 (50 \(\mu\)M), wortmannin (100 nM) or PI-103 (1 \(\mu\)M) (Figure 2A, and results not shown), although a reduction in the expression level of PTEN was often observed, consistent with the previously proposed PI3K feedback regulation of PTEN.
stability [22]. Significantly, the efficient inhibition of phosphorylation by specific GSK3 and CK2 inhibitors in cultured cells also suggests that other kinases are not responsible for the majority of the phosphorylation seen. These results strongly support the conclusion that in unstimulated cells PTEN is phosphorylated upon Thr<sup>366</sup> and Ser<sup>370</sup>, principally by the protein kinases GSK3 and CK2 respectively, and that Ser<sup>370</sup> phosphorylation acts to prime PTEN for phosphorylation upon Thr<sup>366</sup> by GSK3.

**Thr<sup>366</sup> phosphorylation reduces PTEN stability in glioblastoma cell lines**

Phosphorylation of the C-terminal cluster sites of PTEN (residues 380–385) has been shown to lead to its reduced biological activity in the regulation of PI3K-dependent signalling, probably through an electrostatic shift in PTEN conformation causing reduced association with the plasma membrane and reduced metabolism of PtdIns(3,4,5)P<sub>3</sub> [14,20,34,35]. We sought to investigate whether phosphorylation of Thr<sup>366</sup> and Ser<sup>370</sup> also affected the activity of PTEN, either in vitro or in cells. There was no significant effect of mutation of either phosphorylation site to alanine on the in vitro phosphatase activity of these proteins against the lipid substrate PtdIns(3,4,5)P<sub>3</sub>, the soluble inositol phosphate Ins(1,3,4,5)P<sub>4</sub> of the model peptide substrate poly(GluTyr) (Figure 3, and results not shown). Importantly, there was no indication of a shift in the ratio of activities against PtdIns(3,4,5)P<sub>3</sub> and Ins(1,3,4,5)P<sub>4</sub>, a sensitive measure of C-terminal phosphorylation [29] (Figure 3).

We also addressed the cellular activity of these proteins by expressing them in the PTEN-null glioblastoma cell line U87MG and observing the effect on the activation state of the downstream PtdIns(3,4,5)P<sub>3</sub>−dependent kinase Akt/PKB. In these experiments, expression of wild-type PTEN reduced Akt/PKB activity, whereas PTEN A3 (an alanine triple replacement mutant of Ser<sup>366</sup>, Thr<sup>362</sup> and Thr<sup>366</sup>) had a substantially greater effect than the wild-type enzyme. The effect of PTEN T366A, PTEN S370A or a double mutant was similar to that of the wild-type enzyme (Figure 3). These results suggest that phosphorylation of these latter sites may not directly regulate biological activity in the manner of phosphorylation on the cluster sites Ser<sup>366</sup>, Thr<sup>362</sup> and Thr<sup>366</sup>

During these studies in U87MG cells, it became evident that long-term treatment with GSK3 inhibitors frequently caused a clear increase in PTEN protein levels (see, for example, Figure 2B). Similarly, parallel samples using several preparations of expression vectors or viruses in mammalian cells encoding wild-type PTEN and PTEN T366A or S370A mutants invariably led to greater expression levels of the mutant proteins (see, for example, Figure 3). These results suggested that phosphorylation at Thr<sup>366</sup> might regulate protein stability. To address this possibility, we investigated the effects of PTEN mutation and GSK3 inhibitors on the stability of PTEN as measured using metabolic amino acid labelling and pulse/chase analysis. In order to address the stability of different PTEN mutants and also increase the abundance of PTEN protein in these experiments, we continued to perform these experiments using PTEN proteins expressed in U87MG cells. These experiments showed that PTEN T366A and S370A are both more stable than the wild-type enzyme, and also that treatment of cells with the GSK3 inhibitor CT99021 caused an increase in the stability and expression of wild-type PTEN (Figures 4A, 4B and 4D). As established previously, mutation of three of the C-terminal cluster of phosphorylation sites to alanine (PTEN A3 or PTEN T380A, S382A and T383A) had the opposite effect, reducing the stability of the PTEN protein [14,15].

![Figure 3](image)  **Figure 3** The PTEN phosphorylation sites Thr<sup>366</sup> and Ser<sup>370</sup> do not affect phosphatase activity in vitro or in cells

(A) Bacterially expressed PTEN proteins were assayed in vitro against phosphatidylinositol/ PtdIns(3,4,5)P<sub>3</sub> vesicles (100 ng of enzyme) and against the soluble substrate Ins(1,3,4,5)P<sub>4</sub> (500 ng of enzyme). PTEN 2A and 2D refer to double mutants with either alanine or aspartic acid replacements respectively, of both Thr<sup>366</sup> and Ser<sup>370</sup>. PTEN D3 refers to an aspartic acid triple replacement mutant of Ser<sup>366</sup>, Thr<sup>362</sup> and Thr<sup>366</sup>. Results are shown for each substrate as the mean ± S.E.M. activity from triplicate samples and also the ratio of these two activities, shown as the mean ± S.E.M. ratio from these paired triplicate samples. (B, C) U87MG cells were infected with viruses encoding the indicated PTEN proteins. PTEN A3 refers to an alanine triple replacement mutant of Ser<sup>366</sup>, Thr<sup>362</sup> and Thr<sup>366</sup> at 24 h after infection, cells were lysed and the activity (B) and phosphorylation (C) of endogenous Akt/PKB was determined by immunoprecipitate kinase assay and Western blotting respectively. WT, wild-type.

We performed experiments to address the regulation of PTEN by Thr<sup>366</sup> phosphorylation in other cell types, first in another glioma cell line, T98G, which expresses an endogenous mutant PTEN protein that is catalytically inactive ([36], and results
Destabilization of PTEN by phosphorylation on Thr^{366}

Figure 4 Thr^{366} phosphorylation regulates PTEN stability

The stability of the PTEN proteins indicated was analysed by metabolic ^{35}S amino-acid labelling of U87MG cells infected with viruses encoding wild-type (wt) PTEN, PTEN T366A, PTEN S370A or PTEN A3 (S380A T382A T383A) and chasing with unlabelled amino-acid-containing growth medium for the indicated times. The effects of the GSK3 inhibitor CT99021 on wild-type PTEN stability was also investigated (5 µM; present during both pulse and chase). (A) Results are shown on a log scale as the mean percentage expression from the indicated number of experiments (each performed in duplicate) ± S.E.M. from all data. A Student’s t test indicated that results for all conditions were significantly different from wild-type at both 6 and 8 h (P < 0.05), except PTEN T366A, which was significantly different at 6 h, but at 8 h gave P < 0.1. (B) Immunoprecipitated PTEN proteins from one experiment detected using a phosphorimager. Relatively short chase times were used as this was found to reduce experimental variability. (C, D) The effect of the GSK3 inhibitor CT99021 on PTEN expression is shown in T98G cells (C) and U87MG cells (D). T98G cells expressing an endogenous PTEN protein or U87MG cells infected with viruses expressing wild-type PTEN were treated for 24 or 48 h with either DMSO vehicle or CT99021 before expression of PTEN was assessed by Western blotting for PTEN and β-actin. Quantification of these results is shown in Supplementary Figure 4 at http://www.BiochemJ.org/bj/405/bj4050439add.htm.

Our results establish a role for the phosphorylation of Thr^{366} in regulating the stability of the PTEN protein. Cellular PTEN abundance controls basal levels of PtdIns(3,4,5)P_3 and downstream signalling, and even modest effects on PTEN expression have significant effects both on normal physiology and development and on tumour development in many tissues [11–13,37]. Thus a phosphorylation event that destabilizes the PTEN protein may have an important role in regulating PTEN expression levels in some normal and tumour cells and potentially allow the development of novel therapeutic strategies to stabilize this important tumour suppressor.

We thank the protein and antibody production teams of the Division of Signal Transduction Therapy (DSTT) in Dundee, co-ordinated by James Hastie and Hilary McLauchlan, for purified proteins, and Jenny Bain and Matt Elliott for provision of the kinase inhibitors. We thank the MRC (Medical Research Council), the Association for International Cancer Research, and the pharmaceutical companies of the DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Co., Merck KGaA and Pfizer) for financial support.

REFERENCES


© 2007 Biochemical Society
H. Maccario and others

444

17 Tolkacheva, T., Bottini, N., Pessin, J. E., Lemen, J., Unger, J., Black, D. J. et al. (2001) Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 61, 4985–4989

Received 11 December 2006/10 April 2007; accepted 20 April 2007
Published as BJ Immediate Publication 20 April 2007, doi:10.1042/BJ20061837

© 2007 Biochemical Society